Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer

By Hori Natsuko  

International Journal of Clinical Oncology, Vol. 18, Iss. 3, 2013-06 ,pp. : 435-438

Springer Publishing Company

Access to resources Recommend Favorite

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

By            

International Journal of Oncology, Vol. 44, Iss. 1, 2014-01 ,pp. : 17-26

Spandidos Publications

Access to resources Recommend Favorite

XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study

By Rosati Gerardo   Avallone Antonio   Aprile Giuseppe   Butera Alfredo   Reggiardo Giorgio   Bilancia Domenico  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 257-264

Springer Publishing Company

Access to resources Recommend Favorite

First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?

By Marosi Christine  

CNS Oncology, Vol. 2, Iss. 6, 2013-11 ,pp. : 473-474

Future Medicine

Access to resources Recommend Favorite

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

By Rocha Lima Caio M.   Bayraktar Soley   Flores Aurea M.   MacIntyre Jessica   Montero Alberto   Baranda Joaquina C.   Wallmark John   Portera Chia   Raja Rajiv   Stern Howard   Royer-Joo Stephanie   Amler Lukas C.  

Cancer Investigation, Vol. 30, Iss. 10, 2012-12 ,pp. : 727-731

Informa Healthcare

Access to resources Recommend Favorite